Loading Dose of Unfractionated Heparin for Therapeutic Anticoagulation
For therapeutic anticoagulation with unfractionated heparin, administer an 80 units/kg IV bolus (or a fixed 5,000 unit bolus), followed immediately by a continuous infusion of 18 units/kg/hour (or at least 32,000 units/24 hours). This weight-based dosing regimen achieves therapeutic anticoagulation more rapidly and reduces recurrent thromboembolism compared to fixed, lower-dose regimens.
Evidence-Based Dosing Recommendations
The most robust evidence supports weight-based dosing over fixed dosing. The landmark Raschke study demonstrated that patients receiving weight-adjusted heparin (80 units/kg bolus followed by 18 units/kg/hour infusion) had significantly lower rates of recurrent thromboembolism compared to those receiving fixed doses (5,000-unit bolus followed by 1,000 units/hour) 1. This weight-based approach delivers higher doses within the first 24 hours, which is critical for efficacy.
FDA-Approved Dosing Options
The FDA label provides three acceptable regimens for therapeutic anticoagulation 2:
Continuous IV Infusion (Preferred):
- Initial bolus: 5,000 units IV
- Continuous infusion: 20,000-40,000 units/24 hours
Intermittent IV Injection:
- Initial dose: 10,000 units IV
- Maintenance: 5,000-10,000 units every 4-6 hours
Subcutaneous Administration:
- Initial: 5,000 units IV bolus, then 10,000-20,000 units subcutaneously every 8 hours
- Alternative: 333 units/kg subcutaneously initially, then 250 units/kg every 12 hours
Clinical Context Matters
For Venous Thromboembolism (VTE)
The 80 units/kg bolus followed by 18 units/kg/hour infusion is the standard of care 3, 1, 4. Multiple guidelines consistently recommend this regimen for DVT and pulmonary embolism. Achieving therapeutic aPTT within 24 hours is associated with lower in-hospital and 30-day mortality in patients with acute PE 1.
A critical pitfall: Studies show that patients who fail to achieve therapeutic aPTT within 24 hours have worse outcomes. The efficacy of heparin is critically dose-dependent—underdosing leads to higher recurrence rates 1.
For Acute Coronary Syndromes
Lower doses are recommended: 60-70 units/kg bolus (maximum 4,000-5,000 units) followed by 12-15 units/kg/hour infusion (maximum 1,000 units/hour) for unstable angina and NSTEMI 5, 6. When used with fibrinolytics for STEMI, doses are even lower: approximately 60 units/kg bolus (maximum 4,000 units) and 12 units/kg/hour infusion 1.
This distinction is crucial—using VTE doses for ACS patients, especially those receiving concomitant GP IIb/IIIa inhibitors or fibrinolytics, significantly increases bleeding risk 1.
Monitoring and Dose Adjustment
Target aPTT should be 1.5-2.5 times control (approximately 60-85 seconds), corresponding to anti-factor Xa levels of 0.3-0.7 IU/mL 3, 4, 2. Check aPTT approximately 4 hours after initiating therapy, then at appropriate intervals 2.
Important caveat: The evidence for the "therapeutic range" of aPTT 1.5-2.5 times control is actually weak, based on a single retrospective study from the 1970s that has never been validated in randomized trials 1. However, this remains the accepted standard in clinical practice.
Special Populations
Obese Patients
Recent evidence suggests obese patients may require lower weight-adjusted doses to achieve therapeutic anticoagulation 7, 8, 9. In one study, only 49% of patients achieved target ACT with standard 70-100 units/kg dosing, and body mass index was the only significant predictor of heparin response after weight-based dosing 7. Despite this, underdosing remains common in obese patients, with 89% receiving inadequate bolus doses and 76% receiving inadequate initial infusions 8.
Pediatric Patients
Use preservative-free formulations. Initial dose: 75-100 units/kg IV bolus over 10 minutes, followed by continuous infusion of 25-30 units/kg/hour for infants (highest requirements in those <2 months) or 18-20 units/kg/hour for children >1 year 3, 4, 2.
Critical Safety Considerations
- Monitor platelet counts every 2-3 days from day 4-14 to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of patients receiving UFH 4
- Bleeding risk increases with dose, concomitant antiplatelet agents, recent surgery, age >60 years, and hepatic dysfunction 1
- Avoid intramuscular administration due to hematoma risk 2
- In renal insufficiency, heparin clearance is affected but dose adjustment is generally not required (unlike LMWH)
Why Not LMWH Instead?
Current guidelines actually prefer LMWH or fondaparinux over UFH for most VTE patients (Grade 2C recommendation) 4. LMWH provides more predictable anticoagulation, requires no monitoring, and is associated with lower rates of recurrent VTE, bleeding, and HIT 10. UFH should be reserved for patients requiring rapid reversibility (e.g., high bleeding risk, planned procedures, severe renal insufficiency with CrCl <30 mL/min, or hemodynamically unstable PE where thrombolysis may be needed) 4.